Kiniksa Pharmaceuticals (NASDAQ:KNSA) Announces Earnings Results

Kiniksa Pharmaceuticals (NASDAQ:KNSA) announced its quarterly earnings results on Tuesday. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06), Zacks reports. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. During the same quarter in the prior year, the firm earned $0.35 earnings per share. The business’s revenue was up 46.9% compared to the same quarter last year.

Kiniksa Pharmaceuticals Stock Performance

KNSA opened at $19.83 on Tuesday. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -141.63 and a beta of 0.32. The company has a fifty day moving average of $19.69 and a 200 day moving average of $22.63. Kiniksa Pharmaceuticals has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Analyst Upgrades and Downgrades

KNSA has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. Evercore ISI increased their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lifted their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $36.60.

Insiders Place Their Bets

In other news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the sale, the chief operating officer now directly owns 88,975 shares of the company’s stock, valued at approximately $1,622,904. The trade was a 13.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Mark Ragosa sold 8,969 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,092 shares of company stock worth $745,589 in the last 90 days. 54.57% of the stock is currently owned by corporate insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.